DOI QR코드

DOI QR Code

A Case Report of Traditional Korean Medicine-Based Integrative Oncology of Recurrent Cervical Cancer

재발된 자궁경부암 환자의 한의 기반 통합 암 치료에 대한 증례보고

  • Joo, Han-eum (East-West Cancer Center, Daejeon Korean Medicine Hospital of Dae-Jeon University) ;
  • Park, Ji-hye (East-West Cancer Center, Seoul Korean Medicine Hospital of Dae-Jeon University) ;
  • Song, Si-yeon (East-West Cancer Center, Daejeon Korean Medicine Hospital of Dae-Jeon University) ;
  • Cho, Young-min (East-West Cancer Center, Daejeon Korean Medicine Hospital of Dae-Jeon University) ;
  • Park, So-jeong (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) ;
  • Yoo, Hwa-seung (East-West Cancer Center, Daejeon Korean Medicine Hospital of Dae-Jeon University)
  • 주한음 (대전대학교 대전한방병원 동서암센터) ;
  • 박지혜 (대전대학교 서울한방병원 동서암센터) ;
  • 송시연 (대전대학교 대전한방병원 동서암센터) ;
  • 조영민 (대전대학교 대전한방병원 동서암센터) ;
  • 박소정 (부산대학교 한방병원 한방내과) ;
  • 유화승 (대전대학교 대전한방병원 동서암센터)
  • Received : 2022.06.22
  • Accepted : 2022.10.04
  • Published : 2022.09.30

Abstract

Objective: To show a decrease in tumor recurrence and improvement in quality of life in patients with recurrent cervical cancer. Method: A 58-year-old female patient diagnosed with recurrent cervical cancer in February 2021 was treated for 14 months with integrative cancer treatment (ICT) to decrease the tumor size and improve chemotherapy-induced peripheral neuropathy (CIPN) and nausea. The patient underwent chemotherapy or concomitant chemoradiation therapy (CCRT) with ICT. Radiologic outcomes were assessed by abdomen & pelvis computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT) based on the Response Evaluation Criteria in Solid Tumors (RECIST) protocol. Clinical outcomes were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Eastern Cooperative Oncology Group (ECOG), and a numeric rating scale (NRS). Result: During the 14 months of treatment, the size and metabolic activity of the recurrent tumor decreased and underwent partial remission based on RECIST. The NRS scores for CIPN and nausea were improved, and the ECOG score improved from grade 2 to 1. No serious side effects of grade 3 or higher were noted on the NCI-CTCAE test. Conclusion: This case suggests that ICT may have a synergetic effect with chemotherapy or radiotherapy for recurrent cervical cancer.

Keywords

Acknowledgement

이 연구는 보건복지부 한국보건산업진흥원 한의약선도기술개발사업의 지원에 의하여 이루어진 것임(과제고유번호:HI19C1046).

References

  1. Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Kroea in 2019. Sejong: Ministry of Health and Welfare; 2019, p. 1-52.
  2. National Comprehensive Cancer Network. Cervical Cancer; 2022, p. 1-90.
  3. Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med 2014 February 20; 370(8):734-43. https://doi.org/10.1056/NEJMoa1309748
  4. Hsiao YH, Lin CW, Wang PH, Hsin MC, Yang SF. The Potential of Chinese Herbal Medicines in the Treatment of Cervical Cancer. Integr Cancer Ther 2019;18:1534735419861693.
  5. Oh SY, Kim MS, Joo JC, Song YS. Efficacy of Herbal medicine as an Adjunctive Therapy of Chemotherapy for Cervical Cancer: A Systematic Review and Meta-analysis. J Physiol & Pathol Korean Med 2020;34(5):255-62. https://doi.org/10.15188/kjopp.2020.10.34.5.255
  6. Campos LS, Limberger LF, Stein AT, Caldas JM. Survival after Laparoscopic versus Abdominal Radical Hysterectomy in Early Cervical Cancer: A Randomized Controlled Trial. Asian Pac J Cancer Prev 2021;22(1):93-7. https://doi.org/10.31557/APJCP.2021.22.1.93
  7. Kim SI, Lee JW, Hong JY, Lee SJ, Park DC, Yoon JH. Comparison of abdominal and minimally invasive radical hysterectomy in patients with early stage cervical cancer. Int J Med Sci 2021; 18(5):1312-17. https://doi.org/10.7150/ijms.55017
  8. Foucher T, Hennebert C, Dabi Y, Ouldamer L, Lavoue V, Dion L. Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group. J Clin Med 2020 Nov 12;9(11):3646. https://doi.org/10.3390/jcm9113646
  9. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, LM Landrum, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). The Lancet 2017;390(10103) :1654-63. https://doi.org/10.1016/S0140-6736(17)31607-0
  10. Lee NH, Yoon DH, Yoo HS, Cho JH, Son CG, Lee YW, et al. Changes of Serum VEGF, bFGF levels and platelet counts in 100 Cancer Patients treated with Hang-Am-Dan. Korean J Orient Int Med 2005;26(4):753-60.
  11. Choi WC, Jung HS, Kim KS, Lee SK, Yoon SW, Park JH, et al. Rhus verniciflua Stokes against Advanced Cancer:A Perspective from the Korean Integrative Cancer Center. J Biomed Biotechonol 2012;2012:874276.
  12. Schoen-Angerer T, Wilkens J, Kienle GS, Kiene H, Vagedes J. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case series. PermJ 2015 Fall;19(4):76-83. https://doi.org/10.7812/TPP/15-018
  13. Majeed M, Hakeen KR, Rehman RU. Mistletoe lectins: From interconnecting proteins to potential tumour inhibiting agents. Phytomedicine Plus 2021;1(3):100039. https://doi.org/10.1016/j.phyplu.2021.100039
  14. Grossarth-Maricek R, Ziegler R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 2008 Mar 31;13(3):107-20.
  15. Son MK, Jung KH, Lee HS, Lee HS, Kim SJ. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Oncol Rep 2013 Aug;30(2):801-8. https://doi.org/10.3892/or.2013.2517
  16. Hong SW, Jung KH, Lee HS, Son MK, Yan HH, Kang NS, et al. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 2013 Sep;34(9):2156-69. https://doi.org/10.1093/carcin/bgt159
  17. Staff NP, Grisold A, Gristold W, Windebank AJ. Chemotherapy-Induced Peripheral Neuropathy: A Current Review. Ann Neurol 2017 June; 81(6):772-81. https://doi.org/10.1002/ana.24951
  18. Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and Treatment for Chemotherapy -Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. Curr Neuropharmacol 2019;17(2):184-96. https://doi.org/10.2174/1570159X15666170915143217
  19. Kim EH, Yoon JH, Lee JY, Yoon SW. The Therapeutic Efficacy of Acupuncture for Chemotherapy-Induced Peripheral Neuropahty: A Systematic Review and Meta-Analysis. J Int Korean Med 2020;41(3):350-61. https://doi.org/10.22246/jikm.2020.41.3.350